Literature DB >> 18172525

Staged single-ventricle palliation in an infant with hemoglobin SC disease.

Mark A Law1, Zoann Dreyer, Jeffrey S Heinle, Heather A Dickerson.   

Abstract

Staged single-ventricle palliation is used to treat many cyanotic congenital heart diseases. Hemoglobin sickle cell disease is associated with anemia and significant vascular sickling sequelae, which increase the risk associated with single-ventricle palliation. To our knowledge, there are no reports in the English-language medical literature of single-ventricle palliation having been performed on a patient who had either sickle cell anemia or sickle cell-hemoglobin C disease. Herein, we discuss our clinical and surgical management of an infant with tricuspid atresia type IA and hemoglobin sickle cell disease who survived single-ventricle palliative procedures through the 2nd stage of a bidirectional Glenn anastomosis.

Entities:  

Keywords:  Anastomosis, surgical; heart defects, congenital/surgery; hemoglobin C; hemoglobin SC disease/blood/complications/physiopathology/surgery/therapy; hemoglobin, sickle/analysis; infant, newborn; treatment outcome

Mesh:

Year:  2007        PMID: 18172525      PMCID: PMC2170486     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  11 in total

1.  THE COEXISTENCE OF SICKLE CELL DISEASE AND CONGENITAL HEART DISEASE: A REPORT OF THREE CASES, WITH REPAIR UNDER CARDIOPULMONARY BY-PASS IN TWO.

Authors:  L C HARRIS; M E HAGGARD; L B TRAVS
Journal:  Pediatrics       Date:  1964-04       Impact factor: 7.124

Review 2.  Late complications associated with the Fontan circulation.

Authors:  Marshall L Jacobs; Glenn Pelletier
Journal:  Cardiol Young       Date:  2006-02       Impact factor: 1.093

3.  Coronary artery bypass graft surgery in a patient with haemoglobin SC disease.

Authors:  W A Marchant; S Wright; J B Porter
Journal:  Anaesthesia       Date:  2001-07       Impact factor: 6.955

4.  Acute normovolemic red cell exchange for cardiopulmonary bypass in sickle cell disease.

Authors:  G Shulman; C McQuitty; R A Vertrees; V R Conti
Journal:  Ann Thorac Surg       Date:  1998-05       Impact factor: 4.330

5.  Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group.

Authors:  L Neumayr; M Koshy; C Haberkern; A N Earles; R Bellevue; K Hassell; S Miller; D Black; E Vichinsky
Journal:  Am J Hematol       Date:  1998-02       Impact factor: 10.047

6.  Definitive palliation with cavopulmonary or aortopulmonary shunts for adults with single ventricle physiology.

Authors:  M A Gatzoulis; M D Munk; W G Williams; G D Webb
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

7.  Cardiopulmonary bypass in sickle cell anaemia. Report of five cases.

Authors:  S Balasundaram; C G Duran; Z al-Halees; M Kassay
Journal:  J Cardiovasc Surg (Torino)       Date:  1991 Mar-Apr       Impact factor: 1.888

8.  Chronic pulmonary disorders in sickle cell disease: findings at thin-section CT.

Authors:  S L Aquino; G Gamsu; J V Fahy; S Claster; S H Embury; W C Mentzer; E P Vichinsky
Journal:  Radiology       Date:  1994-12       Impact factor: 11.105

Review 9.  The paradox of hemoglobin SC disease.

Authors:  Ronald L Nagel; Mary E Fabry; Martin H Steinberg
Journal:  Blood Rev       Date:  2003-09       Impact factor: 8.250

10.  Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors.

Authors:  Darleen R Powars; Alan Hiti; Emily Ramicone; Cage Johnson; Linda Chan
Journal:  Am J Hematol       Date:  2002-07       Impact factor: 10.047

View more
  2 in total

Review 1.  Knowledge insufficient: the management of haemoglobin SC disease.

Authors:  Lydia H Pecker; Beverly A Schaefer; Lori Luchtman-Jones
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

2.  Sickle Cell Disease with Cyanotic Congenital Heart Disease: Long-Term Outcomes in 5 Children.

Authors:  Glen J Iannucci; Olufolake A Adisa; Matthew E Oster; Michael McConnell; William T Mahle
Journal:  Tex Heart Inst J       Date:  2016-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.